Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations GN Tsaousis, E Papadopoulou, A Apessos, K Agiannitopoulos, G Pepe, ... BMC cancer 19, 1-19, 2019 | 162 | 2019 |
Carboplatin and paclitaxel in advanced or metastatic endometrial cancer D Pectasides, N Xiros, G Papaxoinis, E Pectasides, C Sykiotis, ... Gynecologic oncology 109 (2), 250-254, 2008 | 107 | 2008 |
European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes J Hofland, M Falconi, E Christ, JP Castaņo, A Faggiano, A Lamarca, ... Journal of neuroendocrinology 35 (8), e13318, 2023 | 98 | 2023 |
Temozolomide in advanced neuroendocrine neoplasms: pharmacological and clinical aspects A Koumarianou, G Kaltsas, MH Kulke, K Oberg, JR Strosberg, F Spada, ... Neuroendocrinology 101 (4), 274-288, 2015 | 97 | 2015 |
Current best practice in the management of neuroendocrine tumors M Tsoli, E Chatzellis, A Koumarianou, D Kolomodi, G Kaltsas Therapeutic advances in endocrinology and metabolism 10, 2042018818804698, 2019 | 85 | 2019 |
Tumor molecular profiling of NSCLC patients using next generation sequencing N Tsoulos, E Papadopoulou, V Metaxa-Mariatou, G Tsaousis, ... Oncology reports 38 (6), 3419-3429, 2017 | 85 | 2017 |
Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab AK Koutras, AG Antonacopoulou, AG Eleftheraki, FI Dimitrakopoulos, ... The pharmacogenomics journal 12 (6), 468-475, 2012 | 81 | 2012 |
European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours B Kos‐Kudła, JP Castaņo, T Denecke, E Grande, A Kjaer, A Koumarianou, ... Journal of neuroendocrinology 35 (12), e13343, 2023 | 80 | 2023 |
Progressive muscle relaxation as a supportive intervention for cancer patients undergoing chemotherapy: a systematic review P Pelekasis, I Matsouka, A Koumarianou Palliative & supportive care 15 (4), 465-473, 2017 | 78 | 2017 |
Trefoil factor-2, human spasmolytic polypeptide, promotes branching morphogenesis in MCF-7 cells. EN Lalani, R Williams, Y Jayaram, C Gilbert, KS Chaudhary, LS Siu, ... Laboratory Investigation; a Journal of Technical Methods and Pathology 79 (5 …, 1999 | 74 | 1999 |
A review of psychosocial interventions targeting families of children with cancer A Koumarianou, AE Symeonidi, A Kattamis, K Linardatou, GP Chrousos, ... Palliative & supportive care 19 (1), 103-118, 2021 | 69 | 2021 |
Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours A Koumarianou, S Antoniou, G Kanakis, N Economopoulos, ... Endocrine-related cancer 19 (1), L1-L4, 2012 | 68 | 2012 |
Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study D Pectasides, M Pectasides, D Farmakis, A Gaglia, A Koumarianou, ... Gynecologic oncology 95 (1), 165-172, 2004 | 65 | 2004 |
Activity and safety of standard and prolonged capecitabine/temozolomide administration in patients with advanced neuroendocrine neoplasms E Chatzellis, A Angelousi, K Daskalakis, M Tsoli, KI Alexandraki, ... Neuroendocrinology 109 (4), 333-345, 2019 | 63 | 2019 |
Pigmented Bowen's disease Papageorgiou, Koumarianou, Chu British Journal of Dermatology 138 (3), 515-518, 1998 | 63 | 1998 |
Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients E Papadopoulou, N Tsoulos, K Tsantikidi, V Metaxa-Mariatou, PE Stamou, ... PloS one 14 (12), e0226853, 2019 | 57 | 2019 |
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours A Rinke, V Ambrosini, C Dromain, R Garcia‐Carbonero, A Haji, ... Journal of neuroendocrinology 35 (6), e13309, 2023 | 56 | 2023 |
Cisplatin-based chemotherapy for Merkel cell carcinoma of the skin D Pectasides, M Pectasides, A Psyrri, A Koumarianou, N Xiros, ... Cancer investigation 24 (8), 780-785, 2006 | 56 | 2006 |
Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer A Anestis, P Sarantis, S Theocharis, I Zoi, D Tryfonopoulos, ... Journal of cancer research and clinical oncology 145, 1221-1233, 2019 | 52 | 2019 |
Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab G Fountzilas, C Christodoulou, M Bobos, V Kotoula, AG Eleftheraki, ... Journal of translational medicine 10, 1-13, 2012 | 50 | 2012 |